Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Li, You ^a   Wang, Xiaosheng ^a   Vural, Suleyman ^a   Mishra, Nitish K ^a   Cowan, Kenneth H ^b   Guda, Chittibabu ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTOME;

ANO7 GENE; ARL6IP5 GENE; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CASE CONTROL STUDY; CENPJ GENE; CONTROLLED STUDY; DIFFERENTIALLY MUTATED GENE; ERBB2 GENE; ESP8 GENE; EXOME; GENE; GENE MUTATION; HUMAN; KIAA0922 GENE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PPP2R4 GENE; PRCP GENE; PROTEIN STABILITY; PROTEIN STRUCTURE; RAET1E GENE; SELP GENE; SINGLE NUCLEOTIDE VARIATION; SP4 GENE; ADULT; BREAST TUMOR; DNA SEQUENCE; FEMALE; GENETIC ASSOCIATION STUDY; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EXOME; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTOME;

EID: 84925861916     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119383     Document Type: Article

References (88)

1. American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc. 2013.
2. Hutchinson L (2010) Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol 7: 669-670. doi: 10.1038/nrclinonc.2010.192 PMID: 21116236
3. Polyak K (2011) Heterogeneity in breast cancer. J Clin Invest 121: 3786-3788. doi: 10.1172/JCI60534 PMID: 21965334
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752. PMID: 10963602
5. Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11: 313-324. PMID: 15898220
6. Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F, Glas AM (2010) Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights 5: 129-138. doi: 10.4137/BMI.S6184 PMID: 21151591
7. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218. doi: 10.1038/nature12213 PMID: 23770567
8. Kittaneh M, Montero AJ, Gluck S (2013) Molecular profiling for breast cancer: A comprehensive review. Biomark Cancer 5: 61-70. doi: 10.4137/BIC.S9455 PMID: 24250234
9. Network TCGA (2012) Comprehensivemolecular portraits of human breast tumours. Nature 490: 61-70. doi: 10.1038/nature11412 PMID: 23000897
10. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. (2014) Emergence of Constitutively Active Estrogen Receptor-alpha Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 20: 1757-1767. doi: 10.1158/1078-0432. CCR-13-2332 PMID: 24398047
11. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3: 224-237. doi: 10.1158/ 2159-8290.CD-12-0349 PMID: 23220880
12. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409. doi: 10. 1038/nature11154 PMID: 22722202
13. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. (1996) Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56: 471-474. PMID: 8564955
14. FastQC. Available: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
15. Fastx Toolkit. Available: http://hannonlab.cshl.edu/fastx-toolkit/.
16. Li H, Durbin R (2010) Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595. doi: 10.1093/bioinformatics/btp698 PMID: 20080505
17. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. (2010) The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297-1303. doi: 10.1101/gr.107524.110 PMID: 20644199
18. Van der Auwera GA CM, Hartl C, Poplin R, del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella K, Altshuler D, Gabriel S, DePristo M (2013) From FastQ Data to High-Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline. Current Protocols in Bioinformatics 43. PMID: 24509512
19. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43: 491-498. doi: 10.1038/ng.806 PMID: 21478889
20. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from highthroughput sequencing data. Nucleic Acids Res 38: e164. doi: 10.1093/nar/gkq603 PMID: 20601685
21. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-3814. PMID: 12824425
22. Y B, Y H (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 57: 289-300.
23. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y (2007) Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 3: 11-17. PMID: 19455231
24. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, et al. (2012) The Pfam protein families database. Nucleic Acids Res 40: D290-301. doi: 10.1093/nar/gkr1065 PMID: 22127870
25. Gonzalez-Perez A, Lopez-Bigas N (2011) Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet 88: 440-449. doi: 10. 1016/j.ajhg.2011.03.004 PMID: 21457909
26. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249. doi: 10.1038/ nmeth0410-248 PMID: 20354512
27. Clifford RJ, Edmonson MN, Nguyen C, Buetow KH (2004) Large-scale analysis of non-synonymous coding region single nucleotide polymorphisms. Bioinformatics 20: 1006-1014. PMID: 14751981
28. Stone EA, Sidow A (2005) Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. Genome Res 15: 978-986. PMID: 15965030
29. Hunter S, Apweiler R, Attwood TK, Bairoch A, Bateman A, Binns D, et al. (2009) InterPro: the integrative protein signature database. Nucleic Acids Res 37: D211-215. doi: 10.1093/nar/gkn785 PMID: 18940856
30. Kallberg M, Wang H, Wang S, Peng J, Wang Z, Lu H, et al. (2012) Template-based protein structure modeling using the RaptorX web server. Nat Protoc 7: 1511-1522. doi: 10.1038/nprot.2012.085 PMID: 22814390
31. Roy A, Kucukural A, Zhang Y (2010) I-TASSER: A unified platform for automated protein structure and function prediction. Nat Protoc 5: 725-738. doi: 10.1038/nprot.2010.5 PMID: 20360767
32. Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33: W306-310. PMID: 15980478
33. Dehouck Y, Kwasigroch JM, Gilis D, Rooman M (2011) PoPMuSiC 2.1: A web server for the estimation of protein stability changes upon mutation and sequence optimality. BMC Bioinformatics 12: 151. doi: 10.1186/1471-2105-12-151 PMID: 21569468
34. Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34: W239-242. PMID: 16845001
35. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. (2009) Circos: An information aesthetic for comparative genomics. Genome Res 19: 1639-1645. doi: 10.1101/gr.092759.109 PMID: 19541911
36. Yoneda-Kato N, Tomoda K, Umehara M, Arata Y, Kato JY (2005) Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. EMBO J 24: 1739-1749. PMID: 15861129
37. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307-325. PMID: 12897328
38. Chen C, Yang JM, Hu TT, Xu TJ, Yan G, Hu SL, et al. (2013) Prognostic role of human epidermal growth factor receptor in gastric cancer: A systematic review and meta-analysis. Arch Med Res 44: 380-389. doi: 10.1016/j.arcmed.2013.07.001 PMID: 23871709
39. Keen JC, Zhou Q, Park BH, Pettit C, Mack KM, Blair B, et al. (2005) Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. J Biol Chem 280: 29519-29524. PMID: 15965230
40. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM (2007) Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol 21: 1905-1923. PMID: 17505062
41. Calin GA, di Iasio MG, Caprini E, Vorechovsky I, Natali PG, Sozzi G, et al. (2000) Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 19: 1191-1195. PMID: 10713707
42. Ruediger R, Pham HT, Walter G (2001) Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 20: 10-15. PMID: 11244497
43. Alaoui-Jamali MA, Song DJ, Benlimame N, Yen L, Deng X, Hernandez-Perez M, et al. (2003) Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Res 63: 3764-3774. PMID: 12839972
44. Wang J, Yuan Y, Zhou Y, Guo L, Zhang L, Kuai X, et al. (2008) Protein interaction data set highlighted with human Ras-MAPK/PI3K signaling pathways. J Proteome Res 7: 3879-3889. doi: 10.1021/ pr8001645 PMID: 18624398
45. Arndt S, Poser I, Moser M, Bosserhoff AK (2007) Fussel-15, a novel Ski/Sno homolog protein, antagonizes BMP signaling. Mol Cell Neurosci 34: 603-611. PMID: 17292623
46. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T, et al. (2008) Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27: 6322-6333. doi: 10.1038/onc.2008.232 PMID: 18663362
47. Georgescu SP, Li JH, Lu Q, Karas RH, Brown M, Mendelsohn ME (2005) Modulator recognition factor 1, an AT-rich interaction domain family member, is a novel corepressor for estrogen receptor alpha. Mol Endocrinol 19: 2491-2501. PMID: 15941852
48. Davis DA, Singer KE, De La Luz Sierra M, Narazaki M, Yang F, Fales HM, et al. (2005) Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 105: 4561-4568. PMID: 15718415
49. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56. PMID: 11242036
50. Hao R, Bondesson M, Singh AV, Riu A, McCollum CW, Knudsen TB, et al. (2013) Identification of Estrogen Target Genes during Zebrafish Embryonic Development through Transcriptomic Analysis. PLoS One 8: e79020. doi: 10.1371/journal.pone.0079020 PMID: 24223173
51. Meijer D, van Agthoven T, Bosma PT, Nooter K, Dorssers LC (2006) Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4: 379-386. PMID: 16778085
52. Brinkman A, van der Flier S, Kok EM, Dorssers LC (2000) BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92: 112-120. PMID: 10639512
53. Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I, et al. (2006) p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 66: 4672-4680. PMID: 16651418
54. van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn JG, et al. (2000) Bcar1/ p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 92: 120-127. PMID: 10639513
55. Peng B, Sutherland KD, Sum EY, OlayioyeM, Wittlin S, Tang TK, et al. (2002) CPAP is a novel stat5-interacting cofactor that augments stat5-mediated transcriptional activity. Mol Endocrinol 16: 2019-2033. PMID: 12198240
56. Koyanagi M, Hijikata M, Watashi K, Masui O, Shimotohno K (2005) Centrosomal P4.1-associated protein is a new member of transcriptional coactivators for nuclear factor-kappaB. J Biol Chem 280: 12430-12437. PMID: 15687488
57. Barash I (2012) Stat5 in breast cancer: potential oncogenic activity coincides with positive prognosis for the disease. Carcinogenesis 33: 2320-2325. doi: 10.1093/carcin/bgs362 PMID: 23161573
58. Tweardy D, Chang JC (2011) Stat5: from breast development to cancer prognosis, prediction, and progression. J Clin Oncol 29: 2443-2444. doi: 10.1200/JCO.2010.34.2014 PMID: 21576641
59. Shostak K, Chariot A (2011) NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Res 13: 214. doi: 10.1186/bcr2886 PMID: 21867572
60. Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, et al. (2006) Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 66: 4065-4078. PMID: 16618726
61. Chen YJ, Shen MR, Maa MC, Leu TH (2008) Eps8 decreases chemosensitivity and affects survival of cervical cancer patients. Mol Cancer Ther 7: 1376-1385. doi: 10.1158/1535-7163.MCT-07-2388 PMID: 18566210
62. Kikuno R, Nagase T, Waki M, Ohara O (2002) HUGE: A database for human large proteins identified in the Kazusa cDNA sequencing project. Nucleic Acids Res 30: 166-168. PMID: 11752282
63. Maharzi N, Parietti V, Nelson E, Denti S, Robledo-Sarmiento M, Setterblad N, et al. (2013) Identification of TMEM131L as a novel regulator of thymocyte proliferation in humans. J Immunol 190: 6187-6197. doi: 10.4049/jimmunol.1300400 PMID: 23690469
64. Howe LR, Brown AM (2004) Wnt signaling and breast cancer. Cancer Biol Ther 3: 36-41. PMID: 14739782
65. Jutooru I, Chadalapaka G, Lei P, Safe S (2010) Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 285: 25332-25344. doi: 10.1074/jbc.M109.095240 PMID: 20538607
66. Abdelrahim M, Safe S (2005) Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 68: 317-329. PMID: 15883203
67. Mertens-Talcott SU, Noratto GD, Li X, Angel-Morales G, Bertoldi MC, Safe S (2013) Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog 52: 591-602. doi: 10.1002/mc.21893 PMID: 22407812
68. Higgins KJ, Liu S, Abdelrahim M, Yoon K, Vanderlaag K, Porter W, et al. (2006) Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins. Endocrinology 147: 3285-3295. PMID: 16574784
69. Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A, et al. (2013) Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One 8: e63204. doi: 10.1371/journal.pone.0063204 PMID: 23704896
70. Chen M, Geng JG (2006) P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 54: 75-84. PMID: 16648968
71. Gil-Bernabe AM, Lucotti S, Muschel RJ (2013) Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol 162: 433-441. doi: 10.1111/bjh.12381 PMID: 23691951
72. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. (1997) Polymorphisms of alphaadducin and salt sensitivity in patients with essential hypertension. Lancet 349: 1353-1357. PMID: 9149697
73. Kelly TN, Rice TK, Gu D, Hixson JE, Chen J, Liu D, et al. (2009) Novel genetic variants in the alphaadducin and guanine nucleotide binding protein beta-polypeptide 3 genes and salt sensitivity of blood pressure. Am J Hypertens 22: 985-992. doi: 10.1038/ajh.2009.118 PMID: 19574959
74. Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, et al. (2012) Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomarkers Prev 21: 1115-1125. doi: 10.1158/1055-9965.EPI-11-1228 PMID: 22573797
75. Moeller C, Swindell EC, Kispert A, Eichele G (2003) Carboxypeptidase Z (CPZ) modulates Wnt signaling and regulates the development of skeletal elements in the chicken. Development 130: 5103-5111. PMID: 12944424
76. Smyth SS, Sciorra VA, Sigal YJ, Pamuklar Z, Wang Z, Xu Y, et al. (2003) Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity. J Biol Chem 278: 43214-43223. PMID: 12909631
77. Panupinthu N, Lee HY, Mills GB (2010) Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 102: 941-946. doi: 10.1038/sj.bjc.6605588 PMID: 20234370
78. Du J, Sun C, Hu Z, Yang Y, Zhu Y, Zheng D, et al. (2010) Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS One 5: e15940. doi: 10.1371/journal.pone.0015940 PMID: 21209852
79. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, et al. (2004) Plateletderived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114: 1714-1725. PMID: 15599396
80. Duan L, Motchoulski N, Danzer B, Davidovich I, Shariat-Madar Z, Levenson VV (2011) Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. J Biol Chem 286: 2864-2876. doi: 10.1074/jbc. M110.143271 PMID: 21087932
81. Chen N, Debnath J (2010) Autophagy and tumorigenesis. FEBS Lett 584: 1427-1435. doi: 10.1016/j. febslet.2009.12.034 PMID: 20035753
82. Guo W, Chen D, Fan Z, Epstein HF (2011) Differential turnover of myosin chaperone UNC-45A isoforms increases in metastatic human breast cancer. J Mol Biol 412: 365-378. doi: 10.1016/j.jmb.2011. 07.012 PMID: 21802425
83. Wu D, Asiedu M, Wei Q (2009) Myosin-interacting guanine exchange factor (MyoGEF) regulates the invasion activity of MDA-MB-231 breast cancer cells through activation of RhoA and RhoC. Oncogene 28: 2219-2230. doi: 10.1038/onc.2009.96 PMID: 19421144
84. Wu D, Haruta A, Wei Q (2010) GIPC1 interacts with MyoGEF and promotes MDA-MB-231 breast cancer cell invasion. J Biol Chem 285: 28643-28650. doi: 10.1074/jbc.M110.107649 PMID: 20634288
85. Tong SY, Ha SY, Ki KD, Lee JM, Lee SK, Lee KB, et al. (2009) The effects of obesity and HER-2 polymorphisms as risk factors for endometrial cancer in Korean women. BJOG 116: 1046-1052. doi: 10. 1111/j.1471-0528.2009.02186.x PMID: 19438491
86. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39: 870-874. PMID: 17529973
87. Breyer JP, Sanders ME, Airey DC, Cai Q, Yaspan BL, Schuyler PA, et al. (2009) Heritable variation of ERBB2 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 18: 1252-1258. doi: 10.1158/ 1055-9965.EPI-08-1202 PMID: 19336545
88. Prajapati SC, Chauhan SS (2011) Dipeptidyl peptidase III: A multifaceted oligopeptide N-end cutter. FEBS J 278: 3256-3276. doi: 10.1111/j.1742-4658.2011.08275.x PMID: 21794094